ADA updates its “living” standards of medical care in DM

  • American Diabetes Association

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The American Diabetes Association (ADA) has updated its “Living” 2019 Standards of Medical Care in Diabetes.
  • Updates are based on newly published data and FDA label change affecting care for patients with diabetes mellitus (DM) who also have cardiovascular disease and/or chronic kidney disease (CKD).

The updates are:

  • Section 10 was updated based on the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT), in which icosapent ethyl (Vascepa) added to statin therapy for patients with high triglyceride levels reduced cardiovascular events.
    • Standards now include a recommendation that icosapent ethyl be considered for patients with diabetes and atherosclerotic cardiovascular disease or other cardiac risk factors on a statin with controlled low-density lipoprotein cholesterol, but with elevated triglycerides (135-499 mg/dL) to reduce cardiovascular risk.
  • Several revisions in sections 9, 10, and 11 were based on outcomes from The Dapagliflozin Effect on Cardiovascular Events-Thrombosis in Myocardial Infarction 58 (DECLARE-TIMI 58) Trial, in which dapagliflozin (Farxiga) reduced both hospitalization for heart failure and CKD progression.
  • Based on a revision to dapagliflozin prescribing information for patients with diabetes and CKD, the approved use per estimated glomerular filtration rate has been revised from ≥60 mL/minute/1.73 m2 to ≥45 mL/minute/1.73 m2 in Section 11.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit